MoneyWorks4Me

Kerala Ayurveda - Quaterly Results

13 Aug 2026 Evaluate
The sales for the June 2026 quarter moved up 28.25% to Rs. 225.29 millions as compared to Rs. 175.66 millions during the corresponding quarter last year.The Net Loss for the quarter ended June 2026 is Rs. -76.68 millions as compared to Net Profit of Rs. 20.68 millions of corresponding quarter ended June 2025Operating profit Margin for the quarter ended June 2026 slipped to -38.15% as compared to 45.72% of corresponding quarter ended June 2025


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 225.29 175.66 28.25 225.29 175.66 28.25 854.85 726.89 17.60
Other Income 12.78 99.99 -87.22 12.78 99.99 -87.22 179.35 51.71 246.84
PBIDT -38.15 45.72 -183.44 -38.15 45.72 -183.44 -50.81 -74.16 -31.49
Interest 28.09 7.70 264.81 28.09 7.70 264.81 72.70 39.16 85.65
PBDT -66.24 38.02 -274.22 -66.24 38.02 -274.22 -123.51 -113.32 8.99
Depreciation 14.05 12.26 14.60 14.05 12.26 14.60 35.95 21.51 67.13
PBT -80.29 25.76 -411.68 -80.29 25.76 -411.68 -159.46 -134.83 18.27
TAX -3.61 5.08 -171.06 -3.61 5.08 -171.06 -12.05 2.98 -504.36
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -76.68 20.68 -470.79 -76.68 20.68 -470.79 -147.41 -137.81 6.97
Equity 129.95 120.32 8.00 129.95 120.32 8.00 126.90 120.32 5.47
PBIDTM(%) -16.93 26.03 -165.06 -16.93 26.03 -165.06 -5.94 -10.20 -41.74

Kerala Ayurveda Share Price

155.40 -1.80 (-1.15%)
13-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1942.85
Dr. Reddys Labs. 1206.00
Cipla 1461.00
Lupin 2261.00
Zydus Lifesciences 1173.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: